India · Delayed Price · Currency is INR Accolade Statistics
Total Valuation
Bacil Pharma has a market cap or net worth of INR 539.39 million. The enterprise value is 512.45 million.
| Market Cap | 539.39M |
| Enterprise Value | 512.45M |
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bacil Pharma has 14.35 million shares outstanding. The number of shares has decreased by -0.82% in one year.
| Current Share Class | 14.35M |
| Shares Outstanding | 14.35M |
| Shares Change (YoY) | -0.82% |
| Shares Change (QoQ) | +32.51% |
| Owned by Insiders (%) | 7.45% |
| Owned by Institutions (%) | n/a |
| Float | 12.32M |
Valuation Ratios
The trailing PE ratio is 54.46.
| PE Ratio | 54.46 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.12 |
| P/TBV Ratio | 2.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 134.58 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 126.81 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.21, with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.21 |
| Quick Ratio | 16.92 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 3.03% and return on invested capital (ROIC) is -1.18%.
| Return on Equity (ROE) | 3.03% |
| Return on Assets (ROA) | -1.18% |
| Return on Invested Capital (ROIC) | -1.18% |
| Return on Capital Employed (ROCE) | -1.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | 1.35M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Bacil Pharma has paid 34,000 in taxes.
| Income Tax | 34,000 |
| Effective Tax Rate | 0.83% |
Stock Price Statistics
The stock price has increased by +104.57% in the last 52 weeks. The beta is 0.23, so Bacil Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +104.57% |
| 50-Day Moving Average | 40.92 |
| 200-Day Moving Average | 37.00 |
| Relative Strength Index (RSI) | 42.53 |
| Average Volume (20 Days) | 13,195 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.54M |
| Pretax Income | 4.08M |
| Net Income | 4.04M |
| EBITDA | -2.53M |
| EBIT | -2.54M |
| Earnings Per Share (EPS) | 0.69 |
Balance Sheet
The company has 28.57 million in cash and 1.64 million in debt, giving a net cash position of 26.93 million or 1.88 per share.
| Cash & Cash Equivalents | 28.57M |
| Total Debt | 1.64M |
| Net Cash | 26.93M |
| Net Cash Per Share | 1.88 |
| Equity (Book Value) | 254.31M |
| Book Value Per Share | 32.60 |
| Working Capital | 27.39M |
Cash Flow
| Operating Cash Flow | 4.01M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bacil Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.82% |
| Shareholder Yield | n/a |
| Earnings Yield | 0.75% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |